X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs WOCKHARDT LTD. - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS WOCKHARDT LTD. NOVARTIS/
WOCKHARDT LTD.
 
P/E (TTM) x 328.0 -22.0 - View Chart
P/BV x 36.4 2.2 1,630.9% View Chart
Dividend Yield % 1.3 0.0 72,669.0%  

Financials

 NOVARTIS   WOCKHARDT LTD.
EQUITY SHARE DATA
    NOVARTIS
Mar-18
WOCKHARDT LTD.
Mar-18
NOVARTIS/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs7581,012 74.9%   
Low Rs579532 108.9%   
Sales per share (Unadj.) Rs228.4355.9 64.2%  
Earnings per share (Unadj.) Rs31.7-60.3 -52.7%  
Cash flow per share (Unadj.) Rs32.8-46.8 -70.1%  
Dividends per share (Unadj.) Rs10.000.01 100,000.0%  
Dividend yield (eoy) %1.50 115,445.0%  
Book value per share (Unadj.) Rs297.1257.8 115.3%  
Shares outstanding (eoy) m24.69110.63 22.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.2 135.0%   
Avg P/E ratio x21.1-12.8 -164.5%  
P/CF ratio (eoy) x20.4-16.5 -123.6%  
Price / Book Value ratio x2.23.0 75.2%  
Dividend payout %31.50 -189,924.9%   
Avg Mkt Cap Rs m16,50585,379 19.3%   
No. of employees `0000.76.3 10.7%   
Total wages/salary Rs m1,4459,371 15.4%   
Avg. sales/employee Rs Th8,441.36,295.0 134.1%   
Avg. wages/employee Rs Th2,163.61,498.3 144.4%   
Avg. net profit/employee Rs Th1,173.1-1,066.3 -110.0%   
INCOME DATA
Net Sales Rs m5,63939,369 14.3%  
Other income Rs m1,7181,202 142.9%   
Total revenues Rs m7,35740,571 18.1%   
Gross profit Rs m-6318 -341.5%  
Depreciation Rs m251,495 1.7%   
Interest Rs m552,555 2.2%   
Profit before tax Rs m1,575-2,830 -55.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m792257 308.0%   
Profit after tax Rs m784-6,669 -11.8%  
Gross profit margin %-1.10 -2,384.5%  
Effective tax rate %50.3-9.1 -553.3%   
Net profit margin %13.9-16.9 -82.0%  
BALANCE SHEET DATA
Current assets Rs m9,52233,796 28.2%   
Current liabilities Rs m3,29626,917 12.2%   
Net working cap to sales %110.417.5 631.9%  
Current ratio x2.91.3 230.1%  
Inventory Days Days3779 46.1%  
Debtors Days Days2889 31.9%  
Net fixed assets Rs m4639,664 0.1%   
Share capital Rs m123553 22.3%   
"Free" reserves Rs m7,21327,968 25.8%   
Net worth Rs m7,33628,522 25.7%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m11,10581,620 13.6%  
Interest coverage x29.5-0.1 -27,422.7%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.50.5 105.3%   
Return on assets %7.6-5.0 -149.9%  
Return on equity %10.7-23.4 -45.7%  
Return on capital %22.2-7.7 -289.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m619,807 0.6%   
Fx outflow Rs m3,6301,789 203.0%   
Net fx Rs m-3,5708,019 -44.5%   
CASH FLOW
From Operations Rs m1,610684 235.2%  
From Investments Rs m6876,302 10.9%  
From Financial Activity Rs m-2,677-7,695 34.8%  
Net Cashflow Rs m-380-664 57.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 2.3 87.0%  
FIIs % 1.6 7.7 20.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 67,757 61.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - CIPLA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS